Published online Jul 15, 2019. doi: 10.4251/wjgo.v11.i7.509
Peer-review started: February 23, 2019
First decision: April 15, 2019
Revised: April 25, 2019
Accepted: June 12, 2019
Article in press: June 13, 2019
Published online: July 15, 2019
Core tip: Patient-derived organoids are three-dimensional models of human cancer useful for investigating tumor biology and drug discovery. There are now many reports on the utility of organoids in cancer research and personalized therapy. However, none focus on the use of organoid technology in improving outcomes for patients with gastric cancer (GC), which is one of the deadliest cancers worldwide. Our objective is to report the current progress in GC organoid technology in comparison to traditional cancer models and evaluate their potential role in informing personalized clinical decision making for patients with GC.